Carlyle Group Inc.
Institutional investor · Portfolio as of Q4 2024
Top Holdings27 positions
STANDARDAERO INC | 6.7M | $3.9B | 93.2% | $24.76 | 0.00% | 1 qtr | New 99 |
SOLENO THERAPEUTICS INC | 1.4M | $61.8M | 1.5% | $26.90 | +68.38% | 8 qtrssince 2023-Q1 | Decreased 0 |
WERIDE INC SPONSORED ADS | 3.4M | $48.5M | 1.2% | $13.85 | 0.00% | 1 qtr | New 68 |
PONY AI INC | 2.4M | $33.9M | 0.8% | $15.25 | 0.00% | 1 qtr | New 57 |
PHATHOM PHARMACEUTICALS INC | 3.5M | $28.4M | 0.7% | $7.87 | +1.59% | 8 qtrssince 2023-Q1 | Unchanged 0 |
JASPER THERAPEUTICS INC | 1.1M | $22.7M | 0.5% | $18.80 | +11.44% | 8 qtrssince 2023-Q1 | Unchanged 0 |
GETTY IMAGES HOLDINGS INC | 8.7M | $18.8M | 0.5% | $5.55 | -62.16% | 9 qtrssince 2022-Q4 | Decreased 0 |
Invitation Homes Inc | 477,500 | $15.3M | 0.4% | $27.25 | +9.19% | 8 qtrssince 2023-Q1 | Unchanged 0 |
CUBESMART | 220,500 | $9.4M | 0.2% | $32.92 | +16.98% | 10 qtrssince 2022-Q3 | Unchanged 0 |
SEACOR MARINE HLDGS INC | 1.4M | $8.9M | 0.2% | $10.64 | -40.33% | 25 qtrssince 2018-Q4 | Increased 35 |
| 107,214 | $4.1M | 0.1% | $35.43 | -7.14% | 2 qtrssince 2024-Q3 | Unchanged 0 | |
EXICURE INC | 281,636 | $3.8M | 0.1% | $13.76 | +17.40% | 8 qtrssince 2023-Q1 | Increased 44 |
HILLEVAX INC | 1.8M | $3.8M | 0.1% | — | — | 8 qtrssince 2023-Q1 | Unchanged 0 |
Q32 BIO INC | 1.1M | $3.8M | 0.1% | $17.04 | -79.81% | 4 qtrssince 2024-Q1 | Unchanged 0 |
COMPLETE SOLARIA INC | 2M | $3.6M | 0.1% | $1.39 | +25.24% | 6 qtrssince 2023-Q3 | Decreased 0 |
SMART SH GLOBAL LTD | 4.8M | $3.5M | 0.1% | $1.12 | -35.71% | 11 qtrssince 2022-Q2 | Unchanged 0 |
KRISPY KREME INC | 340,748 | $3.4M | 0.1% | $14.92 | -34.24% | 4 qtrssince 2024-Q1 | Unchanged 0 |
| 2.9M | $2.8M | 0.1% | — | — | 8 qtrssince 2023-Q1 | Unchanged 0 | |
ONKURE THERAPEUTICS INC | 269,895 | $2.3M | 0.1% | $8.60 | 0.00% | 1 qtr | New 37 |
SPRUCE BIOSCIENCES INC | 2.9M | $1.2M | 0.0% | $12,318.75 | -80.55% | 8 qtrssince 2023-Q1 | Unchanged 0 |
Carlyle Group Inc. manages $4.1B across 27 positions as of Q4 2024. Top holdings: SARO (93.2%), SLNO (1.5%), WRD (1.2%). Fund DNA: Concentrated Value. HoldingsIntel Score: 1/5.0.
Active quarter - 7 new positions, 6 exits, 2 increased. Top move: SARO (NEW, conviction 99). Portfolio: $4.1B across 27 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR